Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Free Cash Flow (2016 - 2025)

Viking Therapeutics (VKTX) has disclosed Free Cash Flow for 12 consecutive years, with -$85.3 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow fell 173.53% to -$85.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$278.7 million through Dec 2025, down 217.45% year-over-year, with the annual reading at -$278.7 million for FY2025, 217.45% down from the prior year.
  • Free Cash Flow hit -$85.3 million in Q4 2025 for Viking Therapeutics, up from -$94.0 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$6.1 million in Q1 2024 to a low of -$94.0 million in Q3 2025.
  • Historically, Free Cash Flow has averaged -$26.8 million across 5 years, with a median of -$15.6 million in 2022.
  • Biggest five-year swings in Free Cash Flow: surged 75.11% in 2024 and later crashed 753.13% in 2025.
  • Year by year, Free Cash Flow stood at -$12.4 million in 2021, then grew by 11.53% to -$10.9 million in 2022, then crashed by 61.45% to -$17.6 million in 2023, then plummeted by 76.76% to -$31.2 million in 2024, then plummeted by 173.53% to -$85.3 million in 2025.
  • Business Quant data shows Free Cash Flow for VKTX at -$85.3 million in Q4 2025, -$94.0 million in Q3 2025, and -$47.1 million in Q2 2025.